GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Allakos Inc.
Allakos is a biotech company whose stock plummeted after the failure of key clinical trials. Its price chart is a dramatic story of the hopes surrounding its drug and the subsequent crisis, a prime example of binary risks in biotech.
Share prices of companies in the market segment - Pharma immune
Allakos Inc. is a biopharmaceutical company developing drugs to treat eosinophil- and mast cell-related diseases. We've classified it in the Pharma: Immunology category. The chart below shows how investors value companies working in the field of allergic and inflammatory diseases.
Broad Market Index - GURU.Markets
Allakos is a biopharmaceutical company developing drugs to treat diseases caused by eosinophils and mast cells. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ALLK - Daily change in the company's share price Allakos Inc.
Allakos Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for the treatment of allergic and inflammatory diseases.
Daily change in the price of a set of shares in a market segment - Pharma immune
Allakos is a biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. This segment of biotechnology is extremely sensitive to clinical trial results. The chart below illustrates the high volatility typical of this sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Allakos is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Allakos Inc.
Allakos Inc.'s year-over-year performance is the story of its struggle to develop a drug to treat eosinophilic diseases. Its 12-month market cap is entirely dependent on clinical trial data. Failures in key studies have dealt a serious blow, and its valuation now reflects faith in the company's ability to find the right path.
Annual dynamics of market capitalization of the market segment - Pharma immune
Allakos, a late-stage biotech company, develops drugs for the treatment of allergic and inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Allakos, a biopharmaceutical company developing drugs to treat allergic and inflammatory diseases, is a binary outcome story. Its annual market capitalization dynamics fluctuate sharply depending on the results of key clinical trials, which can either confirm or refute its scientific hypothesis.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Allakos Inc.
Allakos is a late-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its allergy treatments is the key event shaping expectations.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Allakos is a biotech company developing antibodies to treat allergic and inflammatory diseases caused by mast cells and eosinophils. The chart below reflects the overall sentiment in the immunopharma sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Allakos is a clinical-stage biotech company developing drugs for allergic and inflammatory diseases. Its shares operate in the world of science, not economics. Their performance is characterized by extreme volatility and is entirely dependent on the results of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Allakos Inc.
Shares of Allakos, a clinical-stage biopharmaceutical company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their drugs for the treatment of allergic and inflammatory diseases. The chart below illustrates how short-term scientific events can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Allakos is a biopharmaceutical company focused on treating allergic and inflammatory diseases. Following clinical trial failures, its prospects are uncertain. This chart illustrates how binary risk in biotech can lead to a sharp divergence from the rest of the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Allakos is a biotech company whose fate depends on scientific data. This chart clearly demonstrates how out of sync its weekly performance can be with the broader market. A single clinical trial announcement can cause massive swings while the S&P 500 remains stagnant.
Market capitalization of the company, segment and market as a whole
ALLK - Market capitalization of the company Allakos Inc.
The market capitalization of Allakos Inc. is a dramatic tale of the rise and fall of hope in biotech. Its price chart reflects the failure of a key drug in late-stage trials, which has virtually wiped out its valuation. The dynamics clearly illustrate the binary risks inherent in drug development.
ALLK - Share of the company's market capitalization Allakos Inc. within the market segment - Pharma immune
Allakos's position in the immunology sector is a high-stakes biotech story. Its market share has fluctuated wildly based on the results of clinical trials of its eosinophil- and mast cell-targeted drugs, demonstrating how much the company's value hinges on scientific data.
Market capitalization of the market segment - Pharma immune
The chart below is a barometer of the biotech sector focused on treating allergic and inflammatory diseases. Allakos is one of the developers in this field. The dynamics on the chart reflect the high volatility and risks associated with clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with allergic and inflammatory diseases. Allakos Inc.'s market cap is based on the value of its antibodies, which target key immune system cells. The line shows the roller coaster of hopes and disappointments in clinical trials on the path to achieving a share of the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
ALLK - Book value capitalization of the company Allakos Inc.
The book value of clinical-stage Allakos Inc. is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for antibodies for the treatment of eosinophil- and mast cell-related diseases. The dynamics illustrate how the company is investing in the development of its core asset.
ALLK - Share of the company's book capitalization Allakos Inc. within the market segment - Pharma immune
Allakos's core assets are its R&D laboratories, which focus on diseases associated with eosinophils and mast cells. The chart shows the company's share of this cutting-edge scientific infrastructure, which forms the physical basis for its therapeutic developments.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Allakos, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Allakos is a biotech company focused on treating allergic and inflammatory diseases by targeting specific types of immune cells. Its assets include intellectual property and clinical programs. The chart below shows the financial resources devoted to this complex area of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Allakos Inc.
Allakos is a biotech company whose fate depends on the success of its drug candidates. Its balance sheet is largely cash flowing toward research. The chart below is a heartbeat of investor hopes. Each peak or trough reflects not a change in assets, but rather news about the clinical trials on which everything hinges.
Market to book capitalization ratio in a market segment - Pharma immune
Allakos Inc. is a biotech company developing drugs to treat allergic and inflammatory diseases. Its value depends on the success of its clinical programs. This chart clearly shows how its market valuation is a bet on future drug development.
Market to book capitalization ratio for the market as a whole
Allakos is a biopharmaceutical company developing drugs for the treatment of allergic and inflammatory diseases. Its market valuation, as shown in this chart, is entirely dependent on the clinical trial results of its lead candidate. This is a classic example of biotech with binary risk.
Debts of the company, segment and market as a whole
ALLK - Company debts Allakos Inc.
Allakos, a clinical-stage biotech, is using raised capital to fund its research into allergic and inflammatory diseases. Following late-stage trial failures, this chart shows how the company is attempting to regroup and reinvest its remaining funds into earlier programs.
Market segment debts - Pharma immune
Allakos is a clinical-stage biotech company facing significant setbacks in its allergy drug trials. This chart shows how its debt policy (or lack thereof) reflects this challenging situation and how it is managing its remaining capital to refocus its research and find a path to survival.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Allakos Inc.
Alpine 4 Holdings is a diversified technology holding company that acquires companies across various sectors. This chart provides an overview of the group's overall debt load. It reflects the holding company's financial strategy for funding its subsidiaries and new acquisitions.
Market segment debt to market segment book capitalization - Pharma immune
Allakos is a clinical-stage biotech developing antibodies to treat allergic and inflammatory diseases. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its long-term and risky clinical trials.
Debt to book value of all companies in the market
Allakos Inc. is a clinical-stage biopharmaceutical company studying diseases related to eosinophils and mast cells. Scientific failures can be fatal for such companies. This chart of total market debt shows the overall risk appetite, which directly impacts Allakos's ability to raise capital after receiving inconclusive clinical data.
P/E of the company, segment and market as a whole
P/E - Allakos Inc.
For Allakos, a biopharmaceutical company working in the field of immunology, the P/E ratio is irrelevant. The company has no stable profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' faith in the success of clinical trials.
P/E of the market segment - Pharma immune
Allakos is a clinical-stage biopharmaceutical company developing antibodies to treat diseases caused by eosinophils and mast cells, such as allergic and inflammatory disorders. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors assess the risks and potential of companies operating at the forefront of immunology.
P/E of the market as a whole
Allakos is a clinical-stage biopharmaceutical company developing drugs to treat eosinophil- and mast cell-related diseases, such as allergies and inflammatory conditions. This risk appetite chart helps understand investor sentiment toward biotech companies working on complex immune diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Allakos Inc.
Allakos is a biopharmaceutical company developing antibodies to treat eosinophil- and mast cell-related diseases, such as allergies. This chart reflects market expectations for the success of its clinical programs, despite past failures. Future profits depend on new data.
%20P%2FE%20Allakos%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Allakos-Inc.&v=1772619190784 "Chart of the company's future (projected) P/E Allakos Inc.")
Future (projected) P/E of the market segment - Pharma immune
Allakos is a biotech company focused on treating allergic and inflammatory diseases. This chart shows how investors view its prospects following clinical trial failures. It compares expectations for the potential success of its remaining programs with those of other biopharma companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772619190791 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Allakos is a clinical-stage biopharmaceutical company focused on treating eosinophil- and mast cell-related diseases. Its future depends entirely on the results of clinical trials. This chart, reflecting market optimism, demonstrates the investor appetite for risk required to finance such long-term and uncertain projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772619190798 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Allakos Inc.
Allakos is a clinical-stage biopharmaceutical company focused on diseases associated with eosinophils and mast cells. Its financial performance is driven by the costs of conducting large clinical trials. This chart illustrates the significant investments required to develop drugs for the treatment of complex allergic and inflammatory conditions.
Profit of companies in the market segment - Pharma immune
Allakos is a biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. This graph, showing overall sector profitability, reflects the potential of new therapeutic targets. The success of Allakos' clinical programs could lead to new treatments for millions of patients and have a significant impact on the entire industry.
Overall market profit
Allakos is a clinical-stage biotechnology company focused on treating allergic and inflammatory diseases. Despite past setbacks, the company continues its research. Its history highlights the high risks and volatility of the biotechnology sector, where success depends on the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Allakos Inc.
Allakos is a biopharmaceutical company developing drugs for the treatment of allergic and inflammatory diseases. Future revenue projections are speculative and depend on the results of clinical trials of its antibodies.
%20profit%20of%20the%20company%20Allakos%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Allakos-Inc.&v=1772619190822 "Graph of future (projected) profit of the company Allakos Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Allakos is a biopharmaceutical company developing antibodies to treat eosinophil- and mast cell-related diseases, such as allergies and inflammation. This chart shows revenue forecasts for the entire immunological pharmaceuticals segment. It helps assess how the company's targeted approach compares to overall expectations for this field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772619190825 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Allakos is a biopharmaceutical company developing drugs to treat allergic and inflammatory diseases. Its success depends on the results of clinical trials. This chart, reflecting investor sentiment, is important for Allakos. During periods of market optimism, companies in its sector find it easier to attract the capital needed to continue expensive development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772619190832 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Allakos Inc.
Allakos is a clinical-stage biopharmaceutical company specializing in diseases related to eosinophils and mast cells. This chart, plotting market capitalization against missing revenue, reflects the hopes and disappointments of biotech. Its dynamics show how the company's valuation fluctuates sharply depending on clinical trial results.
P/S market segment - Pharma immune
Allakos Inc. is a biotech company developing therapeutic antibodies for the treatment of eosinophil- and mast cell-related diseases, such as allergies and inflammatory conditions. This chart shows how investors value the immunology sector's revenue, demonstrating the level of expectations for Allakos' clinical development and scientific platform.
P/S of the market as a whole
Allakos Inc. is a clinical-stage biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. Its valuation is dependent on the results of clinical trials. This chart, which displays the average valuation, demonstrates how biotech companies' valuations are dependent on future potential rather than current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Allakos Inc.
Allakos is a clinical-stage biotech company developing drugs to treat allergic and inflammatory diseases. This chart shows the market's estimate of its potential future revenue. It reflects investor confidence in the success of its clinical trials and the commercial potential of its lead candidate.
%20P%2FS%20Allakos%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Allakos-Inc.&v=1772619190911 "The graph of the company's future (projected) P/S Allakos Inc.")
Future (projected) P/S of the market segment - Pharma immune
Allakos is a clinical-stage biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. The chart shows the average estimated future sales in the immunology sector. It helps understand how investors view the company's prospects following the mixed results of its lead drug's clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772619190929 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Allakos (ALLK) is a clinical-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases. Their future depends solely on the results of clinical trials. This market sentiment chart has no bearing on their scientific developments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772619190937 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Allakos Inc.
Allakos is a clinical-stage biotech company focused on treating allergic and inflammatory diseases. It has no sales revenue. Its financial history consists of investments in the development of antibody candidates. The graph will reflect future revenue from licensing or partnerships following successful trials.
Sales of companies in the market segment - Pharma immune
Allakos Inc. is a clinical-stage biopharmaceutical company focused on eosinophil- and mast cell-related diseases. It currently has no revenue. Its future revenue depends on the success of its lead candidate, lirentelimab, in the treatment of various allergic and inflammatory conditions.
Overall market sales
Allakos Inc. is a clinical-stage biopharmaceutical company focused on treating eosinophil- and mast cell-related diseases. Its value is driven by its scientific developments. The overall economic environment, reflected in this chart, influences investor sentiment and the availability of capital to fund lengthy and expensive clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Allakos Inc.
Allakos is a biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. Future revenue depends on the success of its clinical trials. This chart reflects analysts' long-term expectations for its research and development pipeline.
%20sales%20of%20the%20company%20Allakos%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Allakos-Inc.&v=1772619191028 "Schedule of future (projected) sales of the company Allakos Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Allakos Inc. is a biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. This chart shows the outlook for the immunology segment of the pharmaceutical company. It reflects the significant need for new treatments for eosinophil- and mast cell-related diseases, which is Allakos' focus.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772619191045 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Allakos. The company develops drugs to treat eosinophil- and mast cell-related diseases. Funding for its expensive research is directly dependent on investor risk appetite, which is growing in a stable economy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772619191066 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Allakos Inc.
Allakos is a clinical-stage biotech company developing antibodies for the treatment of allergic and inflammatory diseases. This graph reflects its significant investment in research. Future profitability depends entirely on the success of clinical trials and the commercialization of its drugs.
Market segment marginality - Pharma immune
Allakos is a biopharmaceutical company developing antibodies to treat eosinophil- and mast cell-related diseases, such as allergies and inflammatory conditions. Profitability depends on the success of its clinical programs. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential of its developments.
Market marginality as a whole
Allakos is a clinical-stage biopharmaceutical company developing drugs for the treatment of allergic and inflammatory diseases. Its valuation is entirely dependent on the results of clinical trials. This chart reflects the overall risk appetite of investors, which determines how easily biotech companies, even those with a history of failure, can raise capital.
Employees in the company, segment and market as a whole
Number of employees in the company Allakos Inc.
Allakos Inc. is a biopharmaceutical company developing antibodies to treat allergic and inflammatory diseases. This chart reflects the size of the scientific and clinical teams. Significant changes in the chart may be due to the results of key clinical trials, which forces the company to reassess its strategy and staffing.
Share of the company's employees Allakos Inc. within the market segment - Pharma immune
Allakos is a biotech company focused on treating allergic and inflammatory diseases by targeting eosinophils and mast cells. This graph shows the company's share of the total number of scientists in the field of immunology. Its dynamics may reflect ups and downs related to clinical trial results.
Number of employees in the market segment - Pharma immune
Allakos Inc. is a biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. This chart, showing employment in the immunopharmaceutical sector, is important. The growing number of immunologist researchers indicates an intensive search for new targets and treatment approaches for diseases associated with eosinophils and mast cells.
Number of employees in the market as a whole
Allakos is a biotechnology company working on the treatment of allergic and inflammatory diseases. This overall employment chart reflects the economic basis for healthcare funding. A stable economy allows both public and private insurance systems to cover the costs of new, potentially more effective treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Allakos Inc. (ALLK)
Allakos Inc. (ALLK) is a biopharmaceutical company focused on eosinophil- and mast cell-related diseases (allergies, gastrointestinal tract). Like any biotech, their market capitalization is based on their "intellectual capital"—the potential of their R&D platform—rather than on the current productivity of their small staff.
%20of%20the%20company%20Allakos%20Inc.%20(ALLK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Allakos-Inc.-ALLK&v=1772619191216 "Chart of market capitalization per employee (in thousands of dollars) of the company Allakos Inc. (ALLK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Allakos is a clinical-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases. Its market capitalization is a bet on the success of future drugs. This chart illustrates that in biotech, market value is often unrelated to ongoing operations and can be attributed to a very small team of scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772619191220 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Allakos is a clinical-stage biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. Its market capitalization is based on its scientific potential. This chart shows the typical high valuation per employee for biotech, where investors are betting on the future success of a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772619191228 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Allakos Inc. (ALLK)
Allakos is a clinical-stage biotech company focused on treating allergic and inflammatory diseases by targeting mast cells. This is R&D. This chart shows the company's capital burn rate: how much (negative profit) the company spends on each scientist conducting clinical trials.
%20Chart%20Allakos%20Inc.%20(ALLK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Allakos-Inc.-ALLK&v=1772619191232 "Company Profit Per Employee (in thousands of dollars) Chart Allakos Inc. (ALLK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Allakos is a clinical-stage biotech company specializing in eosinophil- and mast cell-related diseases. This chart reflects the efficiency of its R&D management. Negative values are expected, but investors analyze them in the context of the potential for blockbuster drugs in development.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772619191233 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Allakos (ALLK) is a clinical-stage biopharmaceutical company developing antibodies for the treatment of allergic and inflammatory diseases. It is an R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of immunology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772619191252 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Allakos Inc. (ALLK)
Allakos Inc. is a clinical-stage biotech focused on treating allergic and inflammatory diseases. Following a series of clinical trials, this graph shows low revenue. Its future performance depends entirely on the success of its remaining programs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Allakos-Inc.-ALLK&v=1772619191253 "Sales chart per company employee Allakos Inc. (ALLK)")
Sales per employee in the market segment - Pharma immune
Allakos is a clinical-stage biotech company focused on treating allergic and inflammatory diseases (eosinophil-related). It's an R&D company. This chart clearly shows that the company has no commercial revenue. The productivity of its research team is measured solely by progress in clinical trials.
Sales per employee for the market as a whole
Vermilion Energy (VET) is an international oil and gas exploration and production (E&P) company with assets in North America, Europe, and Australia. It is a classic oil and gas producer. This chart for the company's E&P performance shows its production efficiency. Revenue (oil and gas sales) is generated by assets (wells) managed by a relatively small team of engineers and operators. This indicator fluctuates significantly depending on prices.
Short shares by company, segment and market as a whole
Shares shorted by company Allakos Inc. (ALLK)
Allakos (ALLK) is a biotech company that has suffered devastating failures in clinical trials of its key drugs. This chart tracks bearish bets. Shorts reflect the view that the company has no promising assets left.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Allakos-Inc.-ALLK&v=1772619191258 "Short Shares Chart for the Company Allakos Inc. (ALLK)")
Shares shorted by market segment - Pharma immune
Allakos (ALLK) is a biopharmaceutical company developing antibodies to treat allergic and inflammatory diseases. The chart below represents a general short position in the biotech sector, demonstrating investor skepticism about the success of risky clinical trials.
Shares shorted by the overall market
Allakos (ALLK) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ALLK won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Allakos Inc. (ALLK)
This chart for Allakos is a biotech failure story. The company was betting on Lirentelimab for the treatment of allergic diseases (eosinophilic gastritis). The stock was "overheated" (above 70) pending data. The failure of key Phase 3 trials plunged the stock into deep "oversold" territory (below 30), and now the company is searching for a new future.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Allakos-Inc.-ALLK&v=1772619191274 "RSI 14 indicator chart for the company's stock Allakos Inc. (ALLK)")
RSI 14 Market Segment - Pharma immune
Allakos is a biotech company that specializes in eosinophils (a type of immune cell). They focus on treating allergic and inflammatory diseases (gastrointestinal tract). The Pharma-Immune (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is ALLK's growth due to their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
Allakos (ALLK) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALLK (Allakos Inc.)
Allakos is a biotech company focused on treating eosinophilic diseases. This chart shows the average 12-month analyst forecast, which is highly volatile for R&D companies like this. Their target price is essentially a collective bet on the success or failure of their key clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALLK-Allakos-Inc.&v=1772619191320 "A chart showing analyst consensus forecasts for the expected stock price. ALLK (Allakos Inc.)")
The difference between the consensus estimate and the actual stock price ALLK (Allakos Inc.)
Allakos (ALLK) is a biotech company with an all-or-nothing future. It's betting on a breakthrough in the treatment of allergic diseases (eosinophilic gastritis). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, which for ALLK is a binary bet on the success of its key clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALLK-Allakos-Inc.&v=1772619191321 "A chart showing the difference between the consensus forecast and the actual stock price. ALLK (Allakos Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Allakos is a biotech company developing drugs to treat complex allergic and inflammatory diseases (eosinophils). This is high-risk R&D. This chart shows analysts' overall expectations for the entire immunopharma sector. It reflects whether experts believe breakthroughs in this field are possible or whether they expect a "winter" in biotech funding.
Analysts' consensus forecast for the overall market share price
Allakos (ALLK) is a clinical-stage biopharmaceutical company focused on treating complex allergic and inflammatory diseases. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is a clear indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Allakos Inc.
Allakos is a biotech R&D company that has made an all-in-one bet on treating eosinophilic diseases (allergies, gastrointestinal tract). Their path has been marked by R&D failures. This chart is a clear indicator of faith and disappointment. It reflects not sales, but a speculative valuation of their (rebooted) R&D pipeline and their desperate struggle for survival.
AKIMA Market Segment Index - Pharma immune
Allakos is a biopharmaceutical company focused on eosinophils, specific immune cells that cause a number of rare inflammatory diseases. This is a complex and risky area of immunology. This chart compares their composite index to the sector, allowing you to assess how their highly specialized R&D stands out from the competition.
The AKIM Index for the overall market
Allakos is a biotech company developing antibodies to inhibit mast cells and eosinophils in inflammatory diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ALLK, which is recovering from clinical setbacks, compares to overall economic trends.
